The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases
Quick Facts
- Publication title: The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases
- Journal: TRANSL LUNG CANCER R
- Year: 2022
- DOI: 10.21037/tlcr-22-260
- PMID/PMCID: 35529783; PMC9073749
Research overview
This real-word study is aimed to evaluate the clinical outcome of immune checkpoint inhibitor (ICI)-based treatment in lung adenocarcinoma patients with brain metastases (BMs) and explore potential risk factors, with a focus on the spatial distribution of BMs as previous studies suggested spatial heterogeneity on the brain immune microenvironment. This real-word study is aimed to evaluate the clinical outcome of immune checkpoint inhibitor (ICI)-based treatment in lung adenocarcinoma patients with brain metastases (BMs) and explore potential risk factors, with a focus on the spatial distribution of BMs as previous studies suggested spatial heterogeneity on the brain immune microenvironment.
Key findings
Six upregulated miRNAs were identified in patients with cerebellum metastases (N=8) compared with those without (N=7).
The enrichment of differentially expression genes in the KEGG pathways indicated upregulated sulfur metabolism pathway in patients with cerebellum metastases.
Study design
Advanced lung adenocarcinoma patients with non-oncogene-addicted, who received ICI monotherapy or plus chemotherapy, were enrolled.
Intergroup comparisons were performed using Pearson's χ2 or Fisher's exact tests for categorical variables.
The progression-free survival (PFS) was estimated using Kaplan-Meier method and compared using log-rank test.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases Translational Lung Cancer Research. 2022. DOI: 10.21037/tlcr-22-260. PMID/PMCID: 35529783; PMC9073749.